Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–13 of 13 results
Advanced filters: Author: Markus Luster Clear advanced filters

  • Developing chemistries for positive electrodes with large specific capacities and high operating potentials is highly desirable for aqueous zinc batteries. Here, authors report a reversible Se electrode that undergoes ZnSe↔Se↔SeCl4 reaction, combined with Br− /Brn – redox couple as Se revitalizer to enhance cycling performance.

    • Jingwei Du
    • Jiaxu Zhang
    • Minghao Yu
    ResearchOpen Access
    Nature Communications
    Volume: 16, P: 1-10

  • Life expectancy of most patients with differentiated thyroid cancer is normal, so adverse treatment effects should be minimized. Lower activities of radioiodine for ablation of thyroid remnants are non-inferior to higher activities and quality of life can be maintained by preparation of radioiodine remnant ablation using recombinant human thyrotropin.

    • Christoph Reiners
    • Markus Luster
    News & Views
    Nature Reviews Clinical Oncology
    Volume: 9, P: 432-434

  • Total thyroidectomy and subsequent radioiodine ablation improve the outcome of patients with thyroid tumours measuring >1 cm. Best practice guidelines should serve as a basis for clinical decision making in stage I thyroid cancer; however, Haymart et al. report that soft factors, unrelated to clinical presentation, affect the rate of radioiodine ablation.

    • Markus Luster
    • Thomas J. Musholt
    News & Views
    Nature Reviews Endocrinology
    Volume: 9, P: 140-141

  • The management of differentiated thyroid cancer (DTC) is undergoing a paradigm shift, with the recognition that personalized therapies might lead to improved outcomes with reduced severity and frequency of complications. In this Review, Markus Luster and colleagues discuss aspects of DTC management that are suitable for individualization, including the extent of surgery, the dosage of131I and the use of levothyroxine. Advances in imaging techniques and the potential benefit of multitargeted kinase inhibitors are also discussed in the context of DTC management.

    • Markus Luster
    • Theresia Weber
    • Frederik A. Verburg
    Reviews
    Nature Reviews Endocrinology
    Volume: 10, P: 563-574

  • Many questions remain about the efficacy of radioiodine treatment for thyroid remnant ablation and therapy of advanced differentiated thyroid cancer. This Review intends to answer some of these questions taking into account novel insights into the treatment and (re)staging of patients with metastatic disease.

    • Christoph Reiners
    • Heribert Hänscheid
    • Frederik A. Verburg
    Reviews
    Nature Reviews Endocrinology
    Volume: 7, P: 589-595

  • Early attempts at the reinduction of 131I uptake by redifferentiation of 131I-negative differentiated thyroid cancer (DTC) had limited success. Novel therapies targeting the pathways that restore expression of the sodium iodine symporter now offer new hope of success for redifferentiation therapy in DTCs with the BRAFV600E mutation.

    • Frederik A. Verburg
    • Markus Luster
    News & Views
    Nature Reviews Endocrinology
    Volume: 13, P: 9-10

  • More drought episodes are expected due to climate change. The authors test how beech tree metabolism is affected by drought, and show that the recovery is dependent on root carbon storage and increased sink activity in the rhizosphere.

    • Frank Hagedorn
    • Jobin Joseph
    • Matthias Arend
    Research
    Nature Plants
    Volume: 2, P: 1-5

  • TSH-suppressive therapy and the increased risk of cardiovascular disease in patients with differentiated thyroid cancer (DTC) was previously reported. A recent study by Pajamäki and colleagues found that patients with DTC have a higher risk of atrial fibrillation but a lower all-cause cardiovascular death rate. This study offers insights into this effect.

    • Frederik A. Verburg
    • Markus Luster
    News & Views
    Nature Reviews Endocrinology
    Volume: 14, P: 136-137